VivoSeq
Oncology

Cutaneous Melanoma

84

Pipeline Programs↗

7

Active Trials↗

36

Companies Involved↗

Cutaneous Melanoma is a moderately active landscape with 84 programs across 36 companies. The most active players are TuHURA Biosciences, Inc., Sequus Pharmaceuticals, Eisai. 23 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

6/100

Mech. Concentration

4/100

Completion Rate

57/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TuHURA Biosciences, Inc.

1 program

Phase 1S

Sequus Pharmaceuticals

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 1Regeneron logo

Regeneron

2 programs

Phase 2Genmab logo

Genmab

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical2

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Antipd1

Azienda Ospedaliera di Perugia

Phase 15

Bleomycin Sulfate

Sequus Pharmaceuticals

Denileukin Diftitox

Eisai

Sonazoid™

GE Healthcare

PF-08046049

Pfizer

Ifx-Hu2.0

TuHURA Biosciences, Inc.

Phase 235

Epirubicin Hydrochloride

Merck & Co.

Relatlimab

Bristol-Myers Squibb

Sargramostim

Sanofi

Tanespimycin

Bristol-Myers Squibb

Propranolol Hydrochloride

Mylan Pharmaceuticals Inc

Phase 319

Peginterferon Alfa-2b

Merck & Co.

Incomplete Freund's Adjuvant

Eastern Cooperative Oncology Group

Interferon Alfa-2b

Merck & Co.

Paclitaxel

Teva

Talimogene Laherparepvec

Amgen

Approved23

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cefazolin

Baxter Healthcare Corporation

Riluzole

Azurity Pharmaceuticals

Vinorelbine

Pierre Fabre Medicament

Carboplatin

Avyxa

Analysis

Modality Breakdown

73%

Small molecule

58 of 79 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody1215%Protein / enzyme56%Gene therapy23%RNA therapy11%Cell therapy11%

Small molecule leads; the ring shows all 79 classified programs, each share of the total. Modality classified for 99% of 92 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed12 · 38%
Terminated7 · 22%
Recruiting4 · 13%
Active, not recruiting3 · 9%
No longer available2 · 6%
Unknown status2 · 6%
Other2 · 6%

Clinical Trials

Trial Activity

32 trials

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
Recruiting·AAzienda Ospedaliera di Perugia·N/A·NCT07050940·35 enrolled
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Recruiting·IImmatics US, Inc.·Phase 3·NCT06743126·360 enrolled
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Recruiting·UUniversity of Utah·Phase 1/2·NCT06194929·33 enrolled
NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study
Recruiting·AAC Camargo Cancer Center·N/A·NCT07680699·250 enrolled
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Active, not recruiting·MMelanoma Institute Australia·Phase 2·NCT05418972·20 enrolled
Neoadjuvant Atezolizumab in Cutaneous Melanoma
Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT04020809·20 enrolled
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02581930·18 enrolled
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
Completed·GSK logoGSK·Phase 2·NCT00896480·24 enrolled
Use of 852A in Metastatic Cutaneous Melanoma.
Completed·Pfizer logoPfizer·Phase 2·NCT00189332·28 enrolled
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
Completed·GSK logoGSK·Phase 2·NCT01928940·12 enrolled
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00597272·34 enrolled
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Completed·TTuHURA Biosciences, Inc.·Phase 1·NCT03655756·7 enrolled
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Completed·Novartis logoNovartis·Phase 3·NCT01597908·704 enrolled
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Completed·GSK logoGSK·Phase 1·NCT01213472·33 enrolled
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Completed·EMD Serono logoEMD Serono·Phase 2·NCT01693068·194 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)